159 related articles for article (PubMed ID: 31102205)
1. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties.
Yun J; Kim J; Chung J; Hwang SJ; Park SJ
Adv Ther; 2019 Jul; 36(7):1700-1714. PubMed ID: 31102205
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D; Kim J; Yun J; Park SJ
Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
[TBL] [Abstract][Full Text] [Related]
3. In-Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M; Jeong H; Yun J; Kim J; Kim S; Lee Y; Park SJ
Drugs R D; 2023 Dec; 23(4):363-375. PubMed ID: 37606749
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion.
Vimpolsek M; Gottar-Guillier M; Rossy E
Drugs R D; 2019 Jun; 19(2):127-140. PubMed ID: 30810925
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of physicochemical and biological properties of nonreconstituted MYL-1401O vials, reconstituted MYL-1401O suspension in vial, and diluted MYL-1401O suspension in infusion bags (0.9% saline) for extended duration.
Vats B; Goyal P; Mathew Z; Ghosh R; Babu MN; Jadav RS; Nair AM; Subbarao M; Bera A; Prakash Sadasivappa K; Kabadi P; Sarkar A; Honnappa CG; Patnaik US; Singh A; Parambath AV; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):299-311. PubMed ID: 33896318
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Apr; 29(3):590-600. PubMed ID: 35072574
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
Weiser S; Burns C; Zartler ER
J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
[TBL] [Abstract][Full Text] [Related]
8. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
Lee JH; Paek K; Moon JH; Ham S; Song J; Kim S
BioDrugs; 2019 Aug; 33(4):411-422. PubMed ID: 31190280
[TBL] [Abstract][Full Text] [Related]
9. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion.
Guyader GL; Vieillard V; Paul M
J Oncol Pharm Pract; 2021 Jun; 27(4):847-856. PubMed ID: 32660375
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration.
Kaiser PK; Yun J; Kim S; Kim J; Park SJ
Ophthalmol Ther; 2023 Apr; 12(2):985-998. PubMed ID: 36607595
[TBL] [Abstract][Full Text] [Related]
12. Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags.
Nalenz H; Köpf E; Dietel E
Int J Pharm Compd; 2018; 22(5):417-423. PubMed ID: 30384340
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D; Yun J; Hwang SJ; Park SJ
Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330
[TBL] [Abstract][Full Text] [Related]
14. Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags.
Hui A; Yin J; Liu W; Zheng K
Int J Pharm Compd; 2021; 25(3):246-257. PubMed ID: 34125716
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab).
Kim J; Chung J; Park S; Jung S; Kang D
Eur J Hosp Pharm; 2018 May; 25(3):157-164. PubMed ID: 29732144
[TBL] [Abstract][Full Text] [Related]
16. In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion.
Kim SJ; Lee JW; Kang HY; Kim SY; Shin YK; Kim KW; Oh JS; Lim KJ; Kim JY
BioDrugs; 2018 Dec; 32(6):619-625. PubMed ID: 30386977
[TBL] [Abstract][Full Text] [Related]
17. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.
Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Shparyk Y; Moiseyenko V; Bello M; Semiglazov V; Lee Y; Lim J
Eur J Cancer; 2018 Apr; 93():19-27. PubMed ID: 29448072
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar.
Paek K; Kim GW; Ahn SY; Lim JH; Jung D; Kim S; Lee JH
BioDrugs; 2019 Dec; 33(6):661-671. PubMed ID: 31549311
[TBL] [Abstract][Full Text] [Related]
19. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration.
Glover ZW; Gennaro L; Yadav S; Demeule B; Wong PY; Sreedhara A
J Pharm Sci; 2013 Mar; 102(3):794-812. PubMed ID: 23225178
[TBL] [Abstract][Full Text] [Related]
20. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
